Ligand Announces New Presentation Time at the JMP Securities 7th Annual
Healthcare Conference
SAN DIEGO, Jul 09, 2012 (BUSINESS WIRE) -- Ligand Pharmaceuticals Incorporated
(LGND) announced today that John Higgins, President and Chief Executive Officer
of Ligand, will present at the JMP Securities 7th Annual Healthcare Conference on
Thursday, July 12, 2012 at 10:00 a.m. Eastern (7:00 a.m. Pacific Time). The
conference takes place at the Peninsula hotel in New York. Ligand's presentation
had previously been scheduled for 9:30 a.m. Eastern on July 12th.
A live webcast of the presentation will be available on the Company's website
ligand.com. A replay of the presentation will be archived on the site
for 30 days.
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company with a business model that is based upon
the concept of developing or acquiring royalty revenue generating assets and
coupling them to a lean corporate cost structure. Ligand's goal is to produce a
bottom line that supports a sustainably profitable business. By diversifying the
portfolio of assets across numerous technology types, therapeutic areas, drug
targets, and industry partners, we offer investors an opportunity to invest in
the increasingly complicated and unpredictable pharmaceutical industry. In
comparison to its peers, we believe Ligand has assembled one of the largest and
most diversified asset portfolios in the industry with the potential to generate
revenue in the future. These therapies address the unmet medical needs of
patients for a broad spectrum of diseases including diabetes, hepatitis, muscle
wasting, dyslipidemia, anemia, asthma and osteoporosis. Ligand's Captisol
platform technology is a patent protected, chemically modified cyclodextrin with
a structure designed to optimize the solubility and stability of drugs. Ligand
has established multiple alliances with the world's leading pharmaceutical
companies including GlaxoSmithKline, Merck, Pfizer, Eli Lilly & Company, Baxter
International, Bristol-Myers Squibb, Celgene, Onyx Pharmaceuticals, Lundbeck
Inc., The Medicines Company, Curis, Inc. and Rib-X Pharmaceuticals. Please visit
captisol.com for more information on Captisol. For more information on
Ligand, please visit ligand.com.
Follow Ligand on Twitter @Ligand_LGND.
SOURCE: Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated
John Higgins, President and CEO
Erika Luib, Investor Relations
858-550-7896
@Ligand_LGND
or
Lippert/Heilshorn & Associates
Don Markley, 310-691-7100
dmarkley@lhai.com
@LHA_IR_PR |
